The Critical Path to TB Drug Regimens (CPTR) initiative, co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance, is a multi-sectoral effort to overcome the challenges associated with TB drug development and to dramatically accelerate the development of new and impactful TB drug regimens. This innovative partnership brings together the world’s leading pharmaceutical and other drug developers, global regulatory agencies, and civil society organizations to support advances in regulatory science, the development of infrastructure, and other progress needed to facilitate the development and availability of new TB drug treatments.
The regimen development paradigm promoted by the TB Alliance is championed through the CPTR initiative partners. Under this initiative's umbrella, a diverse group of drug developers will allow their compounds to be tested in combination to find the best regimen, regardless of sponsor(s). This collaboration is a testament to a "patient-first" commitment from all parties and the realization that it will take many organizations working in partnership to stop TB’s devastating global effect.
The CPTR initiative also seeks to advance the regulatory science that will allow for the most efficient, accurate, and robust evaluation and application of these new testing models as well as address issues related to the lack of clinical trial capacity and funding.
The TB Alliance coordinates the clinical combination drug development component of this initiative and, in partnership with Johns Hopkins University manages a preclinical combination drug study program that continues to feed the CPTR combination pipeline.
CPTR has the potential to serve as a blueprint for collaboration and development in other disease areas for which combination therapy is standard, such as cancer and Hepatitis C.
For more information on the CPTR Initiative, please visit www.CPTRinitiative.org